DIASORIN ANNOUNCES THE LAUNCH OF ITS NEW LIAISON® SARS-CoV-2 IgM TEST, A NEW FULLY AUTOMATED SEROLOGY KIT AVAILABLE IN EUROPE AND IN THE U.S. TO IDENTIFY THE IMMEDIATE RESPONSE TO SARS-CoV-2 IN COVID-19 PATIENTS

Saluggia - June 30, 2020 - DiaSorin (FTSE MIB: DIA) announced today that it has launched its new LIAISON® SARS-CoV-2 IgM test. The new test is now CE marked and available in the U.S. market, as part of the U.S. Food and Drug Administration’s process for ‘notification of validation and intent to submit an Emergency Use Authorization,’ outlined in the Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised).

The LIAISON® SARS-CoV-2 IgM test uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific IgM antibodies to SARS-CoV-2 in human serum or plasma samples.

The test responds to the need to identify the presence of IgM antibodies in patients who have been infected with SARS-CoV-2 and to enable the distinction between newly infected and past-infected patients.

The LIAISON® SARS-CoV-2 IgM test is intended as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2 and as a tool to analyze the immune response of infected patients. Moreover, COVID-19 early detection through IgM response is key in patient management and population monitoring programs.

The test will be available on over 5,000 LIAISON® XL platforms installed worldwide.

“Our IgM test is an additional diagnostic tool in the fight against COVID-19 that supports decisions to contain the pandemic. This test complements our recently launched molecular and IgG serology solutions and it confirms our full commitment in combating the spread of the infection,” commented Carlo Rosa, CEO of the DiaSorin Group. “Let me thank our scientists who have been able, once again, to develop an innovative and reliable solution against COVID-19 with effectiveness and dedication. This product is part of a portfolio of innovative tools both in molecular and immunoassay technologies that DiaSorin is planning to launch by year end to support the medical community in the differential diagnosis between COVID-19 and other respiratory diseases.”

For additional information, please contact:

Riccardo Fava
Corporate Vice President Communication & Investor Relations
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Emanuela Salvini
Investor Relator
Tel: +39.0161.487567
emanuela.salvini@diasorin.it

DiaSorin
Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field, with 26 companies, 4 branches, 5 manufacturing facilities and 5 research and development centers.
For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.
The extensive diagnostic testing offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.
More info at www.diasoringroup.com